M&T Bank’s Esperion Therapeutics ESPR Stock Holding History

M&T Bank’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-6,190	Closed	-$506K	–	1860
2015 Q2	$506K	Buy	+6,190	New	+$606K	﹤0.01%	1203

Other funds holding ESPR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

M&T Bank's ESPR Position: Q3 2015 in Review

M&T Bank sold out of Esperion Therapeutics (ESPR) in Q3 2015, closing a stake of 6,190 shares — an estimated $506K sold.

M&T Bank first reported a position in ESPR in Q2 2015 and held it in 1 quarter. The position peaked at $506K in Q2 2015. 121 funds tracked by Wall St. Rank hold ESPR as of Q3 2015.

M&T Bank reported no remaining Esperion Therapeutics position as of Q3 2015 after selling out during the quarter.
M&T Bank sold 6,190 Esperion Therapeutics shares in Q3 2015, an estimated $506K.
M&T Bank first reported a position in Esperion Therapeutics in Q2 2015 and held it in 1 quarter.
M&T Bank's Esperion Therapeutics position peaked at $506K in Q2 2015.
121 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2015.

Based on M&T Bank's 13F filing for Q3 2015, filed 13 Nov 2015.